RECRUITING

Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Over-the-counter drugs like acetaminophen (e.g., Tylenol®) can be detrimental. In space, astronauts who have pain and constant discomfort use acetaminophen extensively. Investigators are studying the effects of acetaminophen under space-like conditions since acetaminophen might affect astronauts' health. Investigators also wish to see whether a dietary supplement can reduce some negative effects of acetaminophen. It is believed that acetaminophen promotes the productions of chemicals in the body that could be toxic. In this study, measurements of these chemicals in urine after ingestion of 1 tablet of acetaminophen and compare these measurements to when acetaminophen is taken at the same time as a dietary supplement. This study will also explore whether these products are more abundant when blood is placed under conditions that mimic space. Therefore, this study will collect blood from a few volunteers who took acetaminophen, and acetaminophen with the dietary supplement.

Official Title

Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity

Quick Facts

Study Start:2024-01-15
Study Completion:2025-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06214468

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * n/a
  1. * Individual allergic to acetaminophen or nicotinamide riboside

Contacts and Locations

Study Contact

marie E migaud, PHD
CONTACT
2514104938
mmigaud@southalabama.edu
BENJAMIN CAMPBELL
CONTACT
2513305253
brcampbell@health.southalabams.edu

Principal Investigator

marie migaud, PHD
PRINCIPAL_INVESTIGATOR
University of South Alabama

Study Locations (Sites)

University of South Alabama
Mobile, Alabama, 36604
United States

Collaborators and Investigators

Sponsor: University of South Alabama

  • marie migaud, PHD, PRINCIPAL_INVESTIGATOR, University of South Alabama

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-15
Study Completion Date2025-04-30

Study Record Updates

Study Start Date2024-01-15
Study Completion Date2025-04-30

Terms related to this study

Additional Relevant MeSH Terms

  • Drug Toxicity